Evidence map›Paper›PMID 40616025›Full record

ArticleBMC pulmonary medicine2025

Clinical characteristics of AATD-related COPD patients vary with age at diagnosis: data from the EARCO international registry.

Dilek Karadoğan, María Torres-Duran, Hanan Tanash, Carlota Rodríguez-García, Jens-Ulrik Stæhr Jensen, Angelo Guido Corsico, José Luis López-Campos, Kenneth Chapman, Christian Clarenbach, Catarina Guimaraes and 11 more

Abstract read
In one paragraph

Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Dilek KaradoğanDepartment of Chest Diseases, Faculty of Medicine, Recep Tayyip Erdoğan University, Rize, Türkiye. dilek.karadogan@erdogan.edu.tr.
María Torres-DuranServicio de Neumología, Hospital Álvaro Cunqueiro. NeumoVigo I+i Research Group, IIS Galicia Sur, Vigo, Spain.
Hanan TanashDepartment of Respiratory Medicine and Allergology, Skåne University Hospital, Lund University, Malmö, Sweden.
Carlota Rodríguez-GarcíaServicio de Neumología, Complejo Hospitalario Clínico-Universitario de Santiago, Santiago de Compostela, Spain.
Jens-Ulrik Stæhr JensenSection of Respiratory Medicine, Department of Medicine, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Angelo Guido CorsicoDepartment of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, 27100, Italy.
José Luis López-CamposCentro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Kenneth ChapmanAsthma and Airway Centre, Division of Respiratory Medicine, Department of Medicine, University Health Network, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada.
Christian ClarenbachDivision of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
Catarina GuimaraesPulmonology Department, Hospital da Senhora da Oliveira, Unidade Local de Saúde Alto Ave, Guimarães, Portugal.
Eva BartošovskáDepartment of Pneumology, First Faculty of Medicine, Thomayer Hospital, Charles University, Prague, Czech Republic.
Maria SucenaPulmonology Department, Centro Hospitalar Universitário de Santo António, Porto, Portugal.
Juan Luis Rodríguez-HermosaPulmonology Department, Department of Medicine, School of Medicine, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
José María Hernández-PérezPulmonology Department, Nuestra Señora de Candelaria University Hospital, Santa Cruz de Tenerife, Spain.
Tahsin Gökhan TelatarDepartment of Public Health, Faculty of Medicine, Recep Tayyip Erdoğan University, Rize, Türkiye.
Yelda VarolDepartment of Chest Diseases, İzmir Faculty of Medicine, Dr. Suat Seren Chest Diseases and Surgery Education and Training Hospital, University of Health Sciences, İzmir, Türkiye.
İpek ÖzmenDepartment of Chest Diseases, Hamidiye Faculty of Medicine, Süreyyapaşa Chest Diseases and Surgery Education and Training Hospital, University of Health Sciences, İstanbul, Türkiye.
Seda TuralDepartment of Chest Diseases, Hamidiye Faculty of Medicine, Yedikule Chest Diseases and Surgery Education and Training Hospital, University of Health Sciences, İstanbul, Türkiye.
Alice M TurnerSchool of Health Sciences, University of Birmingham, Birmingham, UK.
Paul EllisSchool of Health Sciences, University of Birmingham, Birmingham, UK.
EARCO study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aims to evaluate the clinical characteristics of COPD patients with AATD according to their age at diagnosis.

methodsData was obtained from the European Alpha-1 Research Collaboration (EARCO) registry, an international prospective cohort study. AATD patients with COPD registered between February 2020 and October 2024 were analysed. Clinical charateristics were compared between groups, stratified by age of AATD diagnosis as follows; <45, 45-65 and ≥65 years. A multivariable logistic regression model explored factors associated with age at diagnosis.

resultsA total of 1,565 AATD-COPD patients were included, with 18.2% receiving an AATD diagnosis at age ≥ 65. In univariate comparisons according to diagnosis age revealed that the prevalence of patients with Pi*ZZ mutation was lower in the ≥ 65 age group (47.1%) compared to the 45-65 (65.5%) and < 45 (78.5%) age groups. In contrast, the prevalence of Pi*SZ and Pi*SS were higher in the ≥ 65 group compared to the younger age groups. The proportion of never-smokers was highest in the ≥ 65 group (39.5%), whereas only 15.3% of patients under 45 were never-smokers. Multivariate analysis showed that; compared to never-smokers, former smoking (OR: 0.08; 95% CI: 0.03-0.23) and current smoking (OR: 0.43; 95% CI: 0.27-0.70) were negatively associated with a diagnosis at age ≥ 65 in all sample. Compared to the Pi*ZZ genotype, among all sample, Pi*SS was associated with more than a 3-fold increased likelihood of diagnosis at age ≥ 65 and when considering only index cases Pi*SZ was associated with diagnosis age of ≥ 65 (OR: 2.01, 95%CI: 1.01-4.04). Among patients with the Pi*ZZ, current smoking was negatively associated (OR:0.24,95%CI: 0.13-0.47) with a diagnosis at age ≥ 65, whereas higher FEV

conclusionPatients diagnosed at an older age had lower tobacco exposure and less severe disease. This suggests that subclinical symptoms may contribute to delays in diagnosis, as COPD features can be subtle or under-recognised until later in life. Our findings highlight the importance of considering AATD in all COPD patients, regardless of age, to avoid missed or delayed diagnoses.

Indexed as

alpha 1-Antitrypsin DeficiencyPulmonary Disease, Chronic ObstructiveAgedAge FactorsEuropeFemaleHumansLogistic ModelsMaleMiddle AgedPrevalenceProspective StudiesRegistriesSmokingAATDCOPDDiagnosis ageElderly

Identifiers

PMID40616025
PMCPMC12231694

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.